Purpose. A possible role for fondaparinux as a bridging agent in the perioperative setting is explored. Summary. Anticoagulation guidelines provide minimal direction on the perioperative use of ...
HYDERABAD, India & BRISBANE, Australia--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE: RDY) and Alchemia Limited, Brisbane, Australia (ASX: ACL) announced today that Dr. Reddy’s has received final ...
PITTSBURGH, Sept. 10, 2014 /PRNewswire/ -- Mylan Inc. MYL, +0.23% today announced that its subsidiary Mylan Ireland Limited has entered into an agreement to acquire the U.S. commercialization, ...
A study has revealed that fondaparinux, a synthetic inhibitor of coagulation factor Xa, is a promising treatment option for patients with acute coronary syndromes. Mehta et al. performed a combined ...
Fondaparinux is associated with lower risks of severe bleeding and death compared with low-molecular-weight heparin (LMWH) in patients with NSTEMI treated in routine clinical practice, supporting ...
Fondaparinux sodium, a synthetic pentasaccharide, is a selective inhibitor of factor Xa, binding selectively with high affinity to antithrombin III, specifically catalyzing the inactivation of factor ...
Mylan Ireland Limited has entered into an agreement to acquire the U.S. rights to Aspen Global’s Arixtra Injection. Arixtra is indicated for the prophylaxis of deep vein thrombosis. Mylan will pay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results